Kyung NAM Pharm

053950 · KOSDAQ · Health Care · SMALL CAP

Updated terms.

Kyung NAM Pharm updated the disclosed terms of an acquisition of Ascendio, now worth US$9.24M.

M&A([Amended] Decision to acquire shares/equity in another company)· FILED 2026-08-10· RCEPT 20260810900675

US$9.24MDeal value
8.4%vs. company assets

Converted at 1 USD ≈ ₩1,417.31 (filing-date rate, 2026-08-10 close)

What happened

Kyung NAM Pharm updated the disclosed terms of an acquisition of Ascendio, now worth US$9.24M.

For context, this deal is worth about 8.4% of the company's own total assets.

TargetAscendio
Deal valueUS$9.24M
vs. company assets8.4%
Filed2026-08-10, [Amended] Decision to acquire shares/equity in another company
SourceDART rcept 20260810900675 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-08-10 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.